Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Inari Medical, Inc. (NASDAQ:NARI – Get Free Report)’s share price fell 4.2% during trading on Friday .The stock traded as low as $49.40 and last traded at $49.60. 412,108 shares changed hands ...

On Tuesday, Inari Medical Inc (NARI) stock saw a decline, ending the day at $79.5 which represents a decrease of $-0.05 or -0.06% from the prior close of $79.55. The stock opened at $79.54 and touched ...

Oppenheimer has recently initiated Inari Medical Inc (NARI) stock to Outperform rating, as announced on December 17, 2024, according to Finviz. Earlier, on September 18, 2024, Stifel had initiated the ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

This compares to the stock's 2.6% loss over the past four weeks. Inari Medical recorded a strong price increase after it announced a definitive agreement to be acquired by Stryker Corporation.

Truist Financial upped their price target on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Canaccord Genuity ...

including price controls, restrictions on coverage and reimbursements. Any unfavorable change in coverage for Inari Medical’s products will likely hurt their adoption, affecting top-line growth.